Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Stopped A company's strategic decision to focus on areas whereit believes it can be competitive and decided to exit Oncology

Conditions

• Lymphoma, Non-Hodgkin's

Interventions

• DRUG: Galiximab

Sponsor

Biogen